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Abstract: Stem cells, a special subset of cells derived from embryo or adult tissues, are 
known to present the characteristics of self-renewal, multiple lineages of differentiation, 
high plastic capability, and long-term maintenance. Recent reports have further suggested 
that neural stem cells (NSCs) derived from the adult hippocampal and subventricular 
regions possess the utilizing potential to develop the transplantation strategies and to 
screen the candidate agents for neurogenesis, neuroprotection, and neuroplasticity in 
neurodegenerative diseases. In this article, we review the roles of NSCs and other stem 
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cells in neuroprotective and neurorestorative therapies for neurological and psychiatric 
diseases. We show the evidences that NSCs play the key roles involved in the pathogenesis 
of several neurodegenerative disorders, including depression, stroke and Parkinson’s 
disease. Moreover, the potential and possible utilities of induced pluripotent stem cells 
(iPS), reprogramming from adult fibroblasts with ectopic expression of four embryonic 
genes, are also reviewed and further discussed. An understanding of the biophysiology of 
stem cells could help us elucidate the pathogenicity and develop new treatments for 
neurodegenerative disorders. In contrast to cell transplantation therapies, the application of 
stem cells can further provide a platform for drug discovery and small molecular testing, 
including Chinese herbal medicines. In addition, the  high-throughput stem cell-based 
systems can be used to elucidate the mechanisms of neuroprotective candidates in 
translation medical research for neurodegenerative diseases. 
Keywords: stem cells; neural stem cells; neuroprotection; neurodegenerative diseases; 
stem cell-based strategy 
 
1. Introduction 
Stem cells are classified into three types according to their abilities to differentiate. The first type is 
totipotent stem cells, which can be implanted in the uterus of a living animal and give rise to a full 
organism. The second type is pluripotent stem cells such as embryonic stem (ES) cells and induced 
pluripotent stem (iPS) cells. They can give rise to every cell of an organism except extraembryonic 
tissues, such as placenta. This limitation restricts pluripotent stem cells from developing into a full 
organism. The third type is multipotent stem cells. They are adult stem cells which only generate 
specific lineages of cells [1]. Neural stem cells (NSCs) are multipotent stem cells which are derived 
from neural tissues, either from the central nervous system or peripheral nervous systems [1]. These 
cells are self-renewing and can give rise to all cell types (neurons, astrocytes and oligodendrocyes) of 
the nervous system through asymmetric cell division [1].   
In the adult brain, NSCs are primarily located in the subventricular zone (SVZ) of the lateral 
ventricle and the subgranular zone (SGZ) of the hippocampal dentate gyrus (Figure 1). In general, the 
quiescent or dormant NSCs might be present and can be derived from multiple areas of the adult brain 
[2-4]. The SVZ and SGZ niches have common cellular niche components which include astroglia, 
ependymal cells, vascular cells, NSC progeny and mature neurons, and common extracellular niche 
signals which include Wnt, Sonic Hedgehog, bone morphogenic protein antagonists, 
membrane-associated Notch signaling, leukemia inhibitory factor, transforming growth factor-alpha, 
fibroblast growth factors, neurotrophins and extracellular matrix. [3]. These cellular and extracellular 
components regulate the behaviors of NSCs in a region-specific manner [3]. For example, SVZ NSCs 
give rise to Dlx2
+ Mash1
+ intermediate progenitor cells which subsequently give rise to PSA-NCAM
+ 
doublecortin
+ (DCX
+) neuroblasts and migrate towards the olfactory bulb (OB). In contrast, SGZ Int.. J. Mol. Sci. 2010, 11 
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NSCs do not differentiate into interneuron-lineage cells like those in the OB, but give rise to local 
glutamatergic excitatory dentate granule cells [3]. The region-specific development of these NSCs is 
not only due to intrinsic characteristics of the NSCs themselves, but also due to the dictation of local 
microenvironment (i.e., the niche). A detail summary of the neurogenic niche can be found in a recent 
review by Ma et al. [3].   
Figure 1. The two niches of neural stem cells (NSCs). The subventricular zone (SVZ) of 
the lateral ventricle and the subgranular zone (SGZ) of the hippocampal dentate gyrus have 
common cellular niche components and extracellular niche signals. The development of 
NSCs of the two niches is different in a region-specific manner. SVZ NSCs give rise to 
Dlx2
+ Mash1
+ intermediate progenitor cells which subsequently give rise to PSA-NCAM
+ 
doublecortin
+ (DCX
+) neuroblasts (NB) and migrate towards the olfactory bulb (OB). SGZ 
NSCs give rise to local glutamatergic excitatory dentate granule cells. RMS: 
rostro-migratory stream; GL: granular layer. Adapted from Ma et al. [3] and Taupin and 
Gage [5]. 
 
Neurogenesis derived from adult NSCs is critical for a plethora of central nervous functions, such as 
spatial learning and memory, mood regulation and motor controls. Growing evidence also suggests the 
significant contribution of adult NSCs to pathological conditions like seizures, brain tumors, mood 
disorders or neurodegenerative diseases [3]. If the biopathological role of adult NSCs can be better Int.. J. Mol. Sci. 2010, 11 
 
2042
understood, therefore, the therapeutic strategies that assist neuroprotection and neurorestoration can be 
framed and tested through collaborative efforts of both basic and translational research. In the 
following sessions, we will introduce the roles of NSCs in the pathogenesis in some psychiatric and 
neurological diseases, and the application of stem cell-based therapies. 
2. Depression and Neurogenesis: Evidence from Neural Stem Cells 
Depression is one of the most common psychiatric disorders, with 10-20% lifetime prevalence [6,7]. 
However, the etiology and pathophysiology of depression still remain unclear. Preclinical and clinical 
studies suggest the involvement of hippocampus in the pathogenesis of depression. Hippocampus 
plays an important role in learning, memory and emotionality [8,9]. It is also one of the primary niches 
of NSCs. Reduction of hippocampal volume was found in patients with posttraumatic stress disorders 
[10]. Magnetic resonance imaging studies also showed a consistent reduction in hippocampal volume 
in patients with depression [11]. Two meta-analyses have demonstrated a reduction in hippocampal 
volume in patients with recurrent depression in comparison to age- and sex-matched controls [12,13]. 
In addition, most antidepressants and environmental interventions that confer antidepressant-like 
behavioral effects stimulate adult hippocampal neurogenesis [11].   
Based on these findings, impaired hippocampal neurogenesis was considered to be one of the 
etiologies of depression. However, recent studies have shown some controversial evidences against the 
previous findings. First, preclinical and pathohistological studies showed that the reduction of 
hippocampal volume might be a result of decreased dendritic complexity and changes in neurophil and 
glial number rather than impaired hippocampal neurogenesis [14-16]. Besides, the ablation of 
neurogenesis did not induce or affect depression-like or anxiety-like behaviors in animals [14,17-19]. 
To date, hippocampal neurogesis is not thought to be involved in the pathogenesis of depression 
[11,20], although the regulation of neurogenesis in adult brain may be required for antidepressant 
treatment [11]. 
Most antidepressant drugs increase the levels of monoamines serotonin (5-hydroxytrytamine; 5-HT) 
and/or noradrenaline (NA); this suggests that biochemical imbalances within the 5-HT/NA systems 
may cause mood disorders. In addition to the regulation of neurotransmitters, antidepressants also have 
both neuroprotective and neurorestorative effects on hippocampal cells. For example, monoamine 
oxidase-A inhibitor moclobemide (MB) can upregulate proliferation of hippocampal progenitor cells 
in chronically stressed mice [21]. MB can also provide neuroprotection by reducing intracellular pH 
and neuronal activity of CA3 hippocampal neurons [22]. A selective serotonin reuptake inhibitor, 
fluoxetine, was used to treat rats with maternal separation. Compared to the rats that did not receive 
fluoxetine, cell proliferation was increased and apoptosis was decreased in the dentate gyrus of the rats 
that receive fluoxetine [23]. To elucidate the molecular mechanism of the neuroprotective and 
neurorestorative effects of antidepressants, NSCs derived from the hippocampal tissues of adult rats 
can be used as a model for the in vitro drug–effect test [24]. 
 Int.. J. Mol. Sci. 2010, 11 
 
2043
Antidepressant and Neuroprotection: Interaction with Neural Stem Cells 
Clinical findings have shown evidence that hippocampal volume in patients with depression is 
reduced in comparison to the volume in healthy people [10]. Furthermore, the clinical studies and 
magnetic resonance imaging (MRI) survey demonstrated that the hippocampal volume decreases in 
patients with depression and post-traumatic stress disorder [6,10]. Increased neurogenesis in the 
hippocampus by the administration of antidepressant drugs can result in altered behavior in 
stress-induced models and patients [14,23]. Moreover, Chen et al. showed the evidence that 
desipramine can promote neurogenesis in hippocampus and reverse the learned behavior in learned 
helplessness rats [25]. Taken together, these observations implicated that adult hippocampal 
neurogenesis is decreased by stress and this process of neuron loss may be involved in both the 
pathogenesis and treatment of mood disorders. 
Neural stem cells (NSCs), derived from hippocampus and other germinal centers of the brain, have 
been isolated and defined as cells with the capacity of self-renewal and multilineage differentiation [1]. 
NSCs also possess the utilizing potential to develop the transplantation strategies and to screen the 
candidate agents for neurogenesis in neurodegenerative diseases [26]. By using in vitro culture of 
NSCs from hippocampus of adult rats, antidepressants of different classes are proved to have 
neuroprotective effects and can assist neurogenesis [27-31].   
Antidepressants can increase the viability and promote the differentiation of NSCs. They also 
decrease the level of proinflammatory cytokines. [27-31]. Antidepressants are able to prevent Fas 
ligand (FasL)- or lipopolysaccharide (LPS)-induced apoptosis of NSCs through the upregulation of 
Bcl-2 and Bcl-XL expression [27-31]. Higher expression level of phosphorylated ERK 1/2 in addition 
to Bcl-2 was detected in NSCs treated with MB, and the expression was inhibited by a MAPK/ERK 
kinase inhibitor PD98059 [29]. The MAPK inhibitor U0126 also enhances the apoptotic activities and 
decreases cell viability in LPS- and imipramine-treated NSCs [30]. These results suggest 
antidepressants upregulate Bcl-2 expression through the MAPK/ERK pathway. 
In addition to MAPK/ERK signaling modulation, cellular FLICE-inhibitory protein (c-FLIP) may 
also be involved in the prevention of apoptosis of NSCs by antidepressant [28]. C-FLIP is a 
cytoplasmic protein that has sequence homology to FLICE (FADD-like IL-1β-converting enzyme) [32]. 
c-FLIP is capable of binding to FADD, but is unable to be cleaved to an active caspase because of a 
substitution of tyrosine from an active site cysteine. The substitution of tyrosine prevents the initiation 
of the death pathway [32,33]. Chiou et al. demonstrated that fluoxetine upregulated the expression of 
c-FLIP [28]. This upregulation involved PI3k/AKT pathway, since administration of PI3-K inhibitor 
LY294002 dose-dependently reduced fluoxetine-mediated activation of c-FLIP promotor and protein 
expression of c-FLIP [28]. 
It has been well-documented that antidepressants present the potential to upregulate the expression 
of brain-derived neurotrophic factor (BDNF) in animal models as well as the patients with depression 
[30,34-37]. BDNF is the most abundant neurotrophin in the brain. It regulates neuronal cell survival, 
differentiation, synaptic strength and morphology [38]. Blocking endogenous BDNF activity leads to 
aggravated death of a subpopulation of hippocampal neurons after global forebrain ischemia [39]. The Int.. J. Mol. Sci. 2010, 11 
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neuroprotective role of endogenous BDNF is further supported by the observed correlation between 
BDNF protein levels and resistance to ischemic damage in hippocampal subregions [40]. Peng et al. 
demonstrated that imipramine, a tricyclic antidepressant, increased Bcl-2 expression and 
differentiation of rat hippocampal NSCs [30].   
Imipramine also decreased apoptotic activities and proinflammatory cytokines, and improved cell 
viability of LPS-treated NSCs. These effects were all achieved through the upregulation of BDNF [30]. 
Taken together, hippocampal neurogenesis is required for antidepressant therapies. Using cultured rat 
hippocampal NSCs, the molecular mechanisms of antidepressant effects are explored, which include 
the MAPK/ERK pathway, the PI3k/AKT pathway, and the upregulation of BDNF, Bcl-2 and c-FLIP. 
3. Diseases of Central Nervous System and Neural Stem Cells – Stem Cell Therapy and the 
Development of New Target Drug 
Diseases of the central nervous system (CNS) such as stroke, traumatic brain injury, dementia, 
Parkinson’s disease or multiple sclerosis, usually cause morbidity and mortality as well as increase 
social and economic burdens of patients and caregivers. However, most treatments for these diseases 
are symptomatic or preventive, and are not effective. Many attempts have been made to develop a 
neuroprotective treatment to reduce the volume of brain injury, but the translation of neuroprotection 
from experimental therapies to clinical use has not been very successful [41]. Along with the 
development of stem cell studies and the discovery of neural stem cells in the adult brain, 
transplantation of stem cells or their derivatives, and mobilization of endogenous stem cells within the 
adult brain have been proposed as future therapies for the CNS diseases [42]. We herein introduce the 
role of stem cell-based therapies in the possible treatment for Parkinson’s disease and ischemic stroke. 
The two diseases have different etiologies and pathophysiologies, and therefore, different strategies of 
treatment are required. 
3.1. Parkinson’s Disease 
Parkinson’s disease (PD) is a neurodegenerative disease. Its main pathology is cellular loss of the 
substantia nigra pars compacta dopamine neurons that project to the striatum [43]. Clinical signs of PD, 
which include rest tremor, rigidity and bradykinesia, are evident when about 80% of striatal dopamine 
and 50% of nigral neurons are lost [44]. Because PD results from the loss of dopaminergic neurons, the 
prospect of utilizing cell replacement therapies has attracted substantial interests. The first attempt was 
to use fetal mesencephalic tissue for transplantation, and the results were successful in the earliest 
reports [42,45,46]. However, not all trials showed beneficial outcomes. The sham surgery-controlled 
study also demonstrated some clinical benefits in younger but not in older patients [47]. Another study 
showed no significant treatment effects [48]. Moreover, fetal mesencephalic transplantation is 
associated with several problems. First, off-medication dyskinesia increased 6-12 months after the 
transplantation in 15-56% of patients [47-49]. Second, graft-induced inflammatory responses might 
influence the longevity of transplanted cells [50]. Third, tissue availability limits the clinical use [42]. 
As a result, fetal mesencephalic transplantation is not recommended as a conventional therapy for PD. Int.. J. Mol. Sci. 2010, 11 
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Graft-induced dyskinesia is thought to be caused by unfavorable composition of the fetal 
mesencephalic grafts. The fetal mesencephalic tissue includes not only dopaminergic but also 
non-dopaminergic neurons [42]. The exclusion of serotonin and GABA neurons, and enrichment of 
substantia nigra dopamine neurons may decrease the occurrence of dyskinesia [50]. To achieve this 
goal, probable solutions include refinement of dissection methods for fetal tissue transplantation, 
isolation of desired cell types and/or removal of unwanted cellular populations using fluorescence- 
and/or magnetic-activated cell sorting (FACS/MACS), and using stem cells (ES cells and iPS cells) as 
an alternative cell source [50]. Recent evidence has shown that dopamine neurons derived from ES 
cells and bone marrow-derived neural progenitors are functional when grafted into parkinsonian rats 
[42,51-52]. Several methods are able to improve the effectiveness of midbrain dopamine neuron 
generation and/or retrieval from stem cells. These include manipulating transcription factor like Nurr1, 
Pitx3 or Lmx1a, co-culture with astrocytes and using fluorescence-activated cell sorting [50]. The 
replacement of fetal tissue by stem cells also solve the problem of availability and ethical issue [50]. 
The ability of deriving large quantities of correctly differentiated dopamine neurons makes stem cells 
promising cell sources for transplantation in PD. 
3.2. Ischemic Stroke 
Ischemic stroke is a major cause of morbidity and mortality worldwide. The only effective 
treatment for acute ischemic stroke is thrombolytic agents such as rt-PA [53]. For patients receiving 
thrombolytic therapy shortly after the stroke (3–4.5 h), only 31-50% of them obtained favorable 
outcomes, and 6.4% of patients developed brain hemorrhage [54]. New therapeutic strategies with 
neuroprotection or neurorestoration are crucial for improving the prognosis of patients with stroke. 
Ischemia affects the behavior and proliferation status of NSCs. For example, focal ischemia of brain 
enhances endogenous neurogenesis, angiogenesis, axonal sprouting and synaptogenesis [41,55]. 
However, the proportion of damaged or dead neurons replaced by the new neurons is small [55]. 
Besides, neurogenesis does not occur in some ischemic regions. This is probably either due to an 
unfavorable microenvironment of the ischemic sites, or because these sites are distant from the SVZ 
and SGZ, which are most abundant in NSCs [55]. Pharmacological treatments aimed at enhancing 
neurogenesis, angiogenesis and axonal outgrowth were successful in animal studies. These included 
erythropoietin, statins, phosphodiesterase 5 inhibitors, granulocyte-colony stimulating factor, nicotinic 
acid and minocycline [41]. Limited clinical data have indicated beneficial therapeutic potential of these 
drugs in human [56], but further clinical survey is required. The difficulties of the cell-replacement 
therapy are due to variable cell types involved in ischemic stroke, which include neurons, astrocytes, 
oligodendrocytes and endothelial cells of blood vessels [41]. Although transplantation of bone 
marrow-derived mesenchymal stem cells promoted functional recovery, the effect was caused by 
activation of endogenous restoration of injured brain rather than cell replacement [41,42,57]. ES cells 
have been demonstrated to have greater developmental potential and more significant survival rate 
than adult stem cells after transplantation [58]. Transplantation of ES cells also recovered behavioral 
dysfunction induced by middle cerebral arterial occlusion in an animal model [59]. However, the Int.. J. Mol. Sci. 2010, 11 
 
2046
ethical consideration, the limited availability and the possibility of immune rejection after 
transplantation restrict the accessibility of ES cells.   
3.3. The Hope and Hype of Induced Pluripotent Stem Cells in Cell Replacement Therapy of 
Neurological Diseases 
The recent progresses in stem cell research have demonstrated that induced pluripotent stem (iPS) 
cells could be generated from mouse embryonic fibroblasts as well as from adult human fi broblasts 
via the retrovirus-mediated transfection of four transcription factors, that is, Oct3/4, Sox2, c-Myc, and 
Klf-4 [60-62]. The development of iPS cells provides an additional option for replacement therapy. 
They are indistinguishable from ES cells in morphology, proliferative abilities, surface antigens, gene 
expression, epigenetic status of pluripotent cell-specific genes, and telomerase activity [62,63]. They 
are also capable of self-renewal and differentiation into three germ layers, offering potential for 
clinical cell therapies [64,65]. Because iPS cells can be derived from the somatic cells, potential 
immune rejection and ethical consideration can be avoided by autologous transplantation. Recently, 
Wernig et al. demonstrated that neuronal and glial cell types could be derived from iPS cells in vitro 
and that transplantation of iPS cell-derived neuronal cells into the brain was able to improve behavior 
in a rat model of PD [66]. We also demonstrated an efficient method to differentiate iPS cells into 
astrocyte-like and neuron-like cells which displayed functional electrophysiological properties [67]. 
Our  in vivo study showed that direct injection of iPS cells into damaged areas of rat cortex 
significantly decreased the infarct size, improved the motor function, attenuated inflammatory 
cytokines, and mediated neuroprotection after middle cerebral artery occlusion (MCAO) [67]. 
Subdural injection of iPS cells with fibrin glue was as effective and as the direct-injection method, and 
provided a safer choice for cell replacement therapy [67]. 
The ability to form teratomas in vivo has been a landmark and routine assay for evaluating the 
pluripotency of ES as well as iPS cells [64,68]. However, teratoma or tumor formation is a 
unacceptable adverse effect for cell transplantation therapy. Preventing teratoma formation or 
tumorgenesis has become an emergent issue [69-73]. One of the methods is elimination of nonneural 
progenitors, which can be achieved by the elaboration of differentiation protocols that allow maximal 
homogeneity of the transplant [74] or by cell sorting before transplantation [75-78]. Exclusion of 
poorly-differentiated ES or iPS cells can also reduce the rate of teratoma or tumor formation [79]. 
Some antioxidants may prevent tumorgenesis after cell transplantation. Resveratrol, a natural 
polyphenol antioxidant, is demonstrated that it can inhibit teratoma formation in vivo [65]. Our recent 
study result also found that docosahexaenoic acid can inhibit teratoma formation in addition to 
promoting dopaminergic differentiation in iPS cells in PD-like rats [80]. It has been only two years 
since the development of iPS cells. Enhancement of effectiveness and eliminating adverse effects of 
this cell-transplantation therapy required more extensive studies. 
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4. Diet and Neurogenesis 
Recent reports suggested that the environmental factors, especially the detrimental factors induced 
by neuronal injury, have a critical impact on adult neurogenesis. Several environmental factors are also 
involved in adult neurogenesis, diet being one of them. Interested readers can refer to a recent 
comprehensive review by [81]. Briefly, The influence of diet on adult neurogenesis comes from four 
domains: meal content, meal texture, meal frequency and calorie intake [81]. With regards to meal 
content, zinc, thiamine and vitamine-A deficiencies decrease cell proliferation in adult hippocampus 
[81]. Similarly, excess in retinoic acid and increased homocysteine levels also decrease or inhibit cell 
proliferation in adult hippocampus. In contrast, low-dose curcumin and flavonoids have beneficial 
effects on adult hippocampal cell proliferation in rodents [81]. It is worthy noting that most flavonoids 
are extensively metabolized in vivo and the bioavailability of flavonoids after the consumption of 
flavonoid-rich food can only reach very low concentrations in human plasma [82]. In order for adult 
hippocampal neurogenesis to take place, the purity of flavonoid intake needs to be high. An example is 
the extract from a traditional Chinese herbal decoction Xiaobuxin-Tang [83]. It is also interesting that 
calorie restriction and extending the time between meals increase adult hippocampal neurogenesis 
while diets with high-fat content are noxious and weaken neurogenesis in male rates [81].   
5. Neural Stem Cell, Chinese Herbs, and New Drug Screening 
Natural plant products and phytochemicals have been used as medicinal agents for hundreds of 
years in oriental medicine [84]. Based on clinical experiences and recent studies, Chinese herbs and 
their constituents can be the sources for the development of new drugs for many important human 
disorders, such as cancers [85,86]. Accumulating evidences have pointed to the fact that some 
herb-derived substances have neuroprotective effects. For example, Lee et al. reported that wogonin, a 
flavonoid derived from the root of Scutellaria baicalensis Georgi, is neuroprotective in vitro and in 
vivo [87]. It has an anti-inflammation effect by inhibiting the activation of TNF-α, interleukin-1β, and 
nitric oxide (NO) production induced by LPS in cultured brain microglia, and protects co-cultured 
PC12 cells against microglial cytotoxicity [87]. In two experimental brain injury models, transient 
global ischemia by 4-vessel occlusion and excitotoxic injury by systemic kainite injection, wogonin 
reduced induction of inflammatory mediators (ex. iNOS and TNF-α) in hippocampus, inhibits 
micorgial activation, and attenuates ischemic death of hippocampal neurons [87]. Tetramethylpyrazine 
(TMP) is another example. It is an alkaloid extracted from the Chinese herbal plant Ligusticum 
wallichii Franchat (chuanxiong). Previous experimental studies have demonstrated its beneficial 
effects on cardic and cerebral blood flow and reperfusion, as well as its role on calcium antagonism, on 
vascular tissues, on ROS scavenger and on inhibition of inflammation [88]. In addition, systemic 
administration of TMP protects neuronal cells from ischemic or traumatic brain or spinal cord injury, 
promotes functional recovery and attenuates learning and memory impairment induced by D-galactose 
in animals [89-92]. Furthermore, systemic administration of TMP following the onset of seizure 
induced by kainite significantly reduced the number of TUNEL-positive cells in hippocampus and 
piriform cortex, indicating TMP attenuates neuronal degeneration and has neuroprotective efficacy Int.. J. Mol. Sci. 2010, 11 
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against neuro-excitotoxic attack [88]. Another popular plant which is used in oriental food and 
medicine, ginger, is able to inhibit β-amyloid peptide-induced cytokine and chemokine expression in 
cultured monocytes [93]. This in vitro study suggests the potential role of ginger in delaying the onset 
and progression of neurodegenerative disorder involving chronically activated microglial cells in 
CNS [93].   
It is also interesting to review the evidence of phytochemicals as sources of antidepressants. Lim et 
al. showed that ginger oil possessed antidepressant-like action by reducing immobility in the forced 
swim test (FST) in mice after the inhalation of ginger oil [94]. Xu et al. also showed that the mixture 
of honokiol and magnolol had an antidepressant effect because the mixture significantly attenuated the 
reduction of 5-HT levels in frontal cortex, hippocampus, striatum, hypothalamus and nucleus 
accumbens, and raised serum corticosterone concentration induced by chronic mild stress (CMS) in 
rats [95]. The mixture of honokiol and magnolol also decreased immobility time in the mouse FST and 
tail suspension test (TST) significantly, and reversed CMS-induced anhedonia in rats [95]. In our 
experiments, we also found that mice treated with Scutellaria baicalensis, Phellodendri Cortex and 
Ligusticum wallichii had increased number of Brd-U positive cells in dentate gyrus and reduced serum 
levels of corticosterone after the exposure to CMS. Compared with those which were exposed to CMS 
alone without the three traditional Chinese medicinal herbs, these animals had increased body weight 
and reduced immobility time in FST [96]. The cellular, biochemical and behavioral effects of the three 
herbs were similar to the effects of fluoxetine and duloxetine [96]. Furthermore, we also found that the 
three traditional Chinese medicinal herbs increased the cell viability of NSCs, with superior effect on 
the index than fluoxetine treatment [96]. These recent progresses not only support the future niche of 
Chinese medicinal herbs as the useful antidepressants, but also indicate the potential of the use of 
NSC-based screening system for new drug discovery and characterization from Chinese herbs and 
medicines. 
6. Conclusions 
The development of stem cell studies has provided a promising future for the treatment of 
neurological and psychiatric diseases in several ways. First, understanding the biology and pathology 
of NSCs will help us elucidate the pathophysiology of several neurological and psychiatric diseases, 
such as depression, Parkinson’s disease or ischemic stroke. The growing knowledge also helps us 
develop neuroprotective and neurorestorative therapies. Second, NSCs can provide a platform to 
clarify the mechanism and to test the efficacy of drugs, including Chinese herbal medicines. Third, the 
development of ES cells and iPS cells make cell transplantation therapies promising in the treatment of 
ischemic stroke or neurodegenerative diseases. There are still lots of unsolved problems like the 
formation of teratomas from implanted stem cells, or the viability and the ability of differentiation of 
implanted cells. In addition, the collaborative efforts of both basic and translational research are 
needed in the future. Finally, stem cell-based neuroprotective and neurorestorative strategies preserve 
the utilizing potential to develop the transplantation strategies and to screen candidate agents for 
neurogenesis, neuroprotection, and neuroplasticity in neurodegenerative diseases. Int.. J. Mol. Sci. 2010, 11 
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